Back to Journals » Oncolytic Virotherapy » Volume 5

Oncolytic virotherapy for pediatric malignancies: future prospects

Authors Waters AM, Friedman GK, Ring EK, Beierle E

Received 10 May 2016

Accepted for publication 24 June 2016

Published 11 August 2016 Volume 2016:5 Pages 73—80


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Editor who approved publication: Dr Faris Farassati

Alicia M Waters,1 Gregory K Friedman,2 Eric K Ring,2 Elizabeth A Beierle1

1Department of Surgery, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; 2Department of Pediatrics, Division of Hematology-Oncology, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA

Abstract: Pediatric solid tumors remain a major health concern, with nearly 16,000 children diagnosed each year. Of those, ~2,000 succumb to their disease, and survivors often suffer from lifelong disability secondary to toxic effects of current treatments. Countless multimodality ­treatment regimens are being explored to make advances against this deadly disease. One targeted treatment approach is oncolytic virotherapy. Conditionally replicating viruses can infect tumor cells while leaving normal cells unharmed. Four viruses have been advanced to pediatric clinical trials, including herpes simplex virus-1, Seneca Valley virus, reovirus, and vaccinia virus. In this review, we discuss the mechanism of action of each virus, pediatric preclinical studies conducted to date, past and ongoing pediatric clinical trials, and potential future direction for these novel viral therapeutics.

Keywords: oncolytic virus, herpes simplex virus, Seneca Valley virus, reovirus, vaccinia

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]